Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIESSE DIAGNOSTICA SENESE SPA

DIESSE Diagnostica Senese S.P.A. manufactures in-vitro diagnostics systems for the hematology, seroimmunology and bac... read more Featured Products: More products

Download Mobile App





DIESSE Diagnostica Unveils CHORUS EVO Immunochemistry Analyzer

By LabMedica International staff writers
Posted on 25 May 2023

Diesse Diagnostica Senese S. More...

p.A. (Rigoni, Italy) is unveiling its new innovative immunochemistry analyzer, the CHORUS EVO, at this year's WorldLab-EuroMedLab.

The cutting-edge DIESSE CHORUS line comprises a compact instrument and consumables for immunometric assays. Known for simplicity, high-quality mono-test results, and reliability, the CHORUS line is the perfect tool for conducting small-batch diagnostic tests. Its design ensures maximum flexibility in managing the workflow of a clinical laboratory. Even when lab automation isn't viable, the CHORUS line stands out as a go-to solution for immediate, simple, and accurate testing. Its mono-test format facilitates operational efficiency and minimal waste, which is a boon for smaller test volumes. This makes CHORUS an excellent resource for Physician Office Laboratories (POLs) and other diagnostic laboratories, providing them with analytical quality and operational efficiency.

In line with developing instruments featuring cutting-edge technology that meet Italian design and its vision of "Diagnostics Evolution", DIESSE has now unveiled the CHORUS EVO immunochemistry analyzer. CHORUS EVO is a new-generation analytical instrument that integrates innovative digital technology, paving the way for the integration of artificial intelligence functions. In order to achieve this, DIESSE is collaborating with the SAIHUB consortium, a network of companies that specialize in applying artificial intelligence in life sciences.

Their collaborative effort is directed towards creating a data platform, to which the instruments will be connected, facilitating a large-scale data accumulation. This setup will enable direct digital communication between the company and individual instruments, making it possible for the company to monitor the instruments through the data platform. Moreover, it will harness beneficial artificial intelligence functions to train the analyzers to enhance their performance and employ predictive diagnostics to preempt machine downtime. The project also plans to incorporate computer vision systems rooted in artificial intelligence to further optimize the diagnostic capabilities of the instruments.

Related Links:
Diesse Diagnostica Senese Spa


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.